- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02595957
Genomic Secondary Findings Research Initiative
The Genomic Services Research Program investigates the impact of returning medically-actionable secondary findings (SF) from genome and exome sequencing. This observational study examines how recipients understand these findings, communicate them to healthcare providers and family members, and adhere to recommended health actions over time.
Key objectives include:
- Assessing clinical utility of SF through healthcare actions and family communication patterns
- Evaluating penetrance of SF-related disorders in an unselected population
- Conducting bespoke phenotyping for selected participants at NIH facilities
The study involves 5,000 participants who have received SF through various NIH sequencing initiatives. Eligible participants include English- or Spanish-speaking individuals aged 1 month and older who have received SF results, with special considerations for minors, decisionally-impaired adults, and pregnant women.
Research focuses on four primary outcomes:
- Recipient responses and perceptions after SF disclosure
- Family-based positive predictive value of SF
- Adherence to medical recommendations
- Health impacts of receiving SF results
This long-term study (2014-2028) represents a significant effort by the National Human Genome Research Institute to understand the real-world implications of genomic medicine.
Upcoming Clinical Trials
-
NCT07826949Not yet recruitingGlioma | Brain Neoplasm | Recurrent High-Grade Gliomas
-
NCT07826962Not yet recruiting
-
NCT07826975Not yet recruiting
-
NCT07826988Not yet recruitingSickle Cell Disease | Vaso-occlusive Crisis
-
NCT07827001RecruitingBrain Cancer | CNS Cancer | Nervous System Cancer | Brain Cancer Metastatic
-
NCT07827027Not yet recruiting
-
NCT07827040RecruitingAdults | Low Vision Digital Assistance | Visual Impairments
-
NCT07827053Not yet recruitingPancreatic Ductal Adenocarcinoma (PDAC)
-
NCT07827066Not yet recruitingSmoking Cessation | AI Agent | Early-Stage Cancer
-
NCT07827131Not yet recruiting